Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.

ESMO real world data and digital oncology·2026

Same author

Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.

ESMO open·2024

Same author

[Prospective controlled study evaluating teleconsultation and tele-semiology for the management of renal colic].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023

Same author

[Alteration of pulmonary epithelial permeability by cathepsin S in chronic obstructive pulmonary disease].

Revue des maladies respiratoires·2023

Same author

French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022

Same author

Comparison of open and robotic-assisted partial nephrectomy approaches using multicentric data (UroCCR-47 study).

Scientific reports·2022

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

A Standardized Acupotomy Protocol For The Treatment of Tenosynovitis of Hand Flexor Tendons In Human Patients

A Standardized Acupotomy Protocol For The Treatment of Tenosynovitis of Hand Flexor Tendons In Human Patients

Published on: May 26, 2026

[Tuna: clinical retrospective study addressing mid-term outcomes].

N Benoist¹, P Bigot, P Colombel

¹Service d'urologie, faculté de médecine d'Angers, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 09, France.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie

|January 13, 2009

Summary

Radiofrequency (Tuna) treatment for benign prostatic hyperplasia (BPH) showed significant symptom improvement with minimal morbidity. However, a high retreatment rate suggests further long-term studies are needed to define Tuna

Related Experiment Videos

Last Updated: Jun 26, 2026

A Standardized Acupotomy Protocol For The Treatment of Tenosynovitis of Hand Flexor Tendons In Human Patients

A Standardized Acupotomy Protocol For The Treatment of Tenosynovitis of Hand Flexor Tendons In Human Patients

Published on: May 26, 2026

Area of Science:

Urology
Minimally Invasive Surgery

Context:

Benign prostatic hyperplasia (BPH) affects a significant portion of the aging male population.
Medical treatment failure necessitates alternative therapeutic options for symptomatic BPH.
Radiofrequency (Tuna) ablation presents a minimally invasive surgical approach.

Purpose:

To evaluate the efficacy and safety of radiofrequency (Tuna) ablation for treating symptomatic benign prostatic hyperplasia (BPH) in patients who have not responded to medical management.
To assess the impact of Tuna on lower urinary tract symptoms (LUTS) and quality of life.
To determine the morbidity associated with the Tuna procedure.

Summary:

A retrospective analysis of 28 patients treated with Tuna for BPH after medical treatment failure was conducted.
Significant improvements were observed in International Prostatic Symptoms Score (IPSS), urinary peak flow (Qmax), post-void residual urine (PVR), and quality of life at a mean follow-up of 20 months.
The procedure demonstrated minimal morbidity, although the retreatment rate was 46.4%.

Impact:

Tuna offers a viable treatment option for symptomatic BPH with favorable short-to-midterm outcomes.
The low morbidity profile makes Tuna an attractive alternative for select patient populations.
Further long-term studies are warranted to establish the definitive role of Tuna in the surgical management of BPH and to address the observed retreatment rates.